Dana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. KDM6A regulates immune response genes in multiple myeloma

    Blood, Vol. 144, Núm. 14, pp. 1508-1520

  2. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2022

  1. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

2021

  1. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  2. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

    Cell Reports, Vol. 19, Núm. 1, pp. 218-224

2016

  1. Targeting vasculogenesis to prevent progression in multiple myeloma

    Leukemia, Vol. 30, Núm. 5, pp. 1103-1115

2015

  1. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

    Cell Reports, Vol. 12, Núm. 8, pp. 1300-1313

2013

  1. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Cancer Cell, Vol. 23, Núm. 5, pp. 677-692

2010

  1. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma

    Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269